Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00244933|
Recruitment Status : Completed
First Posted : October 27, 2005
Results First Posted : February 2, 2015
Last Update Posted : May 14, 2018
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine hydrochloride together with genistein may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine hydrochloride together with genistein works in treating women with stage IV breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Dietary Supplement: genistein Drug: gemcitabine Procedure: Tumor biopsy||Phase 2|
- Determine the objective response rate in patients with stage IV breast cancer treated with gemcitabine hydrochloride and genistein.
- Determine the duration of response and survival of patients treated with this regimen.
- Determine the time to disease progression in patients treated with this regimen.
- Determine the quantitative and qualitative toxic effects of this regimen in these patients.
- Correlate plasma genistein levels with response in patients treated with this regimen.
OUTLINE: Patients receive oral genistein once daily on days -7 to 1. Patients also receive gemcitabine hydrochloride IV on days 1 and 8 and oral genistein once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays|
|Study Start Date :||February 2004|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||October 2009|
Experimental: Gemcitabine, genistein (Novasoy), Tumor biopsy
Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
Dietary Supplement: genistein
Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
Other Name: NovasoyDrug: gemcitabine
Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
Other Names:Procedure: Tumor biopsy
Biopsy of tumor prior to dose of genistein (Novasoy)
- Objective Response Rate by RECIST Criteria Following [ Time Frame: every 2 courses until disease progression or death, up to 24 weeks ]Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- Duration of Response [ Time Frame: From the time the last patient comes off study treatment for one year ]
- Overall Survival [ Time Frame: From the time the last patient comes off study treatment for one year to monitor survival ]
- Time to Disease Progression [ Time Frame: From the time that treatment is initiated until the time restaging indicates progressive disease. ]
- Duration of Survival [ Time Frame: At 1 year following study treatment ]
- Qualitative and Quantitative Toxicities [ Time Frame: 30 days following treatment ]
- Correlate Responses With Plasma Genistein Levels [ Time Frame: At course 1 day -7, course 1 day -1 (before and 4 hours after dose), course 2 day 1 (before and 4 hours after dose) ]
- In Vivo Effects of Genistein in Breast Cancer Tissue Biomarkers (Ki67, TUNEL Assay, p-Akt, NF-kB, Immunohistochemistry and cDNA Microarray Analysis) [ Time Frame: At baseline (pre-genistein treatment) and 7 days following genistein treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244933
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Principal Investigator:||Amy Weise, DO||Barbara Ann Karmanos Cancer Institute|